Repatha (Evolocumab) Missed-Dose Protocol: What to Do and When At a glance Generic name / evolocumab (brand: Repatha) Drug class / PCSK9 monoclonal antibody (IgG2) FDA-approved dosing / 140 mg every 2 weeks OR 420 mg once monthly, subcutaneous Missed-dose window / Take within 7 days of the scheduled date If more than 7 days late / Skip it and resume your next scheduled dose Half-life / approximately 11 to 17 days at steady state Time to steady-state LDL-C lowering / 12 weeks Key trial / FOURIER (N=27,564), 15% relative reduction in major adverse cardiovascular events LDL-C reduction / 59% mean reduction vs
Dosage: 200 to 300 mcg administered subcutaneously twice daily (morning and evening)
Stay up to date with FDA policies and adjust prescriptions accordingly
A normal blood sugar level, per the American Diabetes Association, is less than 100 mg/dL
Natural allelic variation underlying a major fitness trade-off in Arabidopsis thaliana
Moreover, cooperation agreements, license and sale agreements, and opening to promising markets in new economies are improving access
